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Pulmonary arterial hypertension (PAH) is commonly associated with connective tissue diseases (CTDs) including systemic
sclerosis and systemic lupus erythematosus (SLE). The prevalence of PAH in SLE is estimated to be 0.5% to 17.5%. The patho-
physiology of PAH involves multiple mechanisms from vasculitis and in-situ thrombosis to interstitial pulmonary ﬁbrosis which
increases pulmonary vascular resistance, potentially leading to right heart failure. Immune and inﬂammatory mechanisms may
play a signiﬁcant role in the pathogenesis or progression of PAH in patients with CTDs, establishing a role for anti-inﬂammatory
and immunosuppressive therapies. The leading predictors of PAH in SLE are Raynaud phenomenon, anti-U1RNP antibody, and
anticardiolipinantibodypositivity.Theﬁrst-lineofdiagnostictestingforpatientswithsuspectedSLE-associatedPAH(SLE-aPAH)
involves obtaining a Doppler echocardiogram. Once the diagnosis is conﬁrmed by right heart catheterization, SLE-aPAH patients
aregenerallytreatedwithoxygen,anticoagulants,andvasodilators.Althoughtheprognosisandtherapeuticresponsivenessofthese
patients have improved with the addition of intensive immunosuppressive therapies, these treatments are still largely unproven.
Recent data put the one-year survival rate for SLE-aPAH patients at 94%. Pregnant women are most at risk of dying due to
undiagnosed SLE-aPAH, and screening should be considered essential in this population.
1.Introduction
Pulmonary arterial hypertension (PAH) is a complex and
devastating disease. PAH is deﬁned as an increase in mean
pulmonary arterial pressure (mPAP) ≥25mmHg at rest,
pulmonary artery wedge pressure (PAWP), or left ventricular
end diastolic pressure ≤15mmHg and increased pulmonary
vascularresistance(PVR)[1].PAHcanbeidiopathic(IPAH),
heritable, drug, or toxin induced or associated with human
immunodeﬁciency virus infection, portal hypertension, con-
genital heart diseases, schistosomiasis, or chronic hemolytic
anemia. It can also be associated with varied connective tis-
suediseases(CTDs)suchassystemicsclerosis(SSc),systemic
lupus erythematosus (SLE), rheumatoid arthritis (RA), or
mixed connective tissue disease (MCTD). These PAH-asso-
ciatedconditionsarecategorizedintheWorldHealthOrgan-
ization (WHO) Group 1 PAH classiﬁcation [1, 2].
WhilethepathophysiologicpathwayslinkingPAHtoSLE
have not been adequately explored, this paper will address
the key research ﬁndings and available data on this subject,
as derived from an extensive literature review. PAH disease
progression is characterized by narrowing of the pulmonary
arterial bed due to extensive endothelial, adventitial and
smooth muscle dysfunction. Genetic, environmental, and
other predisposing conditions, including vasodilator and
vasoconstrictor imbalance, inﬂammatory and uncontrolled
immune response, and an imbalance between proliferation
and apoptosis [3, 4], lead to constrained blood ﬂow, poten-
tially resulting in increased pulmonary vascular resistance.
Patients with unrecognized PAH or those who are not yet
treated progress to right ventricular dilatation and failure,
which can ultimately lead to death.
Recent intensive immunosuppressive and vasodilator
therapies have shown a lot of promise in treating SLE-
associated PAH (SLE-aPAH). Recent data reveal that one-
year survival rate was notably higher (at 94%) in SLE-
aPAH patients when compared to that for SSc-aPAH patients2 Clinical and Developmental Immunology
Table 1: REVEAL registry demographic and diagnostic comparison.
IPAH CTD SLE-aPAH SSc-aPAH
Total # of patients 1251 641 110 399
Patients newly diagnosed at enrollment (%) 14 15 14 16
Age (years) 50.1 ± 17.5 57.1 ± 13.7 45.5 ± 11.9 61.8 ± 11.1
Sex, (#)
Female 987 578 104 353
Male 264 63 6 46
Race (%)
White 74.8 71.8 37.4 83.9
African-American 11.7 16.5 31.8 10.9
Hispanic 8.3 7.5 17.8 3.6
Other 5.2 4.2 13.1 1.6
Raynaud phenomenon (%) 1.4 26.5 13.6 32.6
Renal insuﬃciency (%) 3.9 6.9 4.6 8.7
Time between diagnostic RHC and enrollment (months) 41.1 ± 44.1 27.2 ± 29.9 34.4 ± 39.1 24.2 ± 24.1
BNP (pg/mL) 245.6 ± 427.2 432.8 ± 789.1 263.8 ± 338.8 552.2 ± 977.8
DLCO (%) 63.6 ± 22.1 44.9 + 18 53.3 ± 19.5 41.2 ± 16.3
Immunosuppressive therapy (%) 1.3 11.9 22 6.8
A l i v e a t 1 y e a r ( % ) 9 38 69 48 2
(at 82%) [5, 6]. The hospitalization rates were also signif-
icantly lower in SLE-aPAH patients. Although the progno-
sis and therapeutic responsiveness of these patients have
improved relative to the better understood SSc-associated
PAH patients (SSc-aPAH), these therapies are still unproven
and require further study.
2. Prevalenceand Demographics
The prevalence of all PAH has been estimated at 15 cases per
million(adults)accordingtothenationalFrenchregistry[7].
Studies from France and Scotland estimated the prevalence
of CTD-associated PAH (CTD-aPAH) to be 2.3 and 10 cases
per million, respectively, within their general population
[7, 8]. The prevalence of PAH in SLE is estimated to be 0.5%
to 43% in some older studies [9–12] and 0.5% to 17.5% in
two newer French studies [13, 14]. The estimated prevalence
rangeiswide,causedbymultiplefactorssuchasvariedpopu-
lationgroups,lackofauniformPAHdeﬁnition,anddiﬀerent
diagnostic approaches (echocardiogram versus right heart
catheterization (RHC)) [9–14]. In a large community-based
lupus cohort from the United Kingdom (n = 288), the prev-
alence of SLE-aPAH was 4.2%. However, the UK study used
echocardiogram, which tends to yield estimated systolic
pulmonary artery pressures that can diﬀer signiﬁcantly from
the “gold standard”, RHC [9].
TheRegistrytoEvaluateEarlyandLong-termPulmonary
Arterial Hypertension Disease Management (REVEAL) is a
54-center longitudinal US based registry for patients with
PAH. It has the largest cohort of patients (n = 2,967) with
PAH conﬁrmed by RHC. The registry included 641 patients
with CTD-aPAH, of which 110 patients had SLE-aPAH,
including approximately 15 patients with newly diagnosed
SLE-aPAH. Table 1 provides a comparative analysis of dem-
ographic and diagnostic features of the IPAH, CTD-aPAH,
SLE-aPAH, and SSc-aPAH patients observed in the registry.
Patients with SLE-aPAH were younger compared to other
CTD-aPAH patients. Both SLE-aPAH and CTD-aPAH pa-
tient groups were comprised predominantly of women who
had similar body mass indices.
Cohort studies, other than REVEAL, have similarly con-
ﬁrmed the SLE-aPAH patients’ demographics: patients are
predominantly females of child-bearing age, from 18 to 40
years, with a female to male ratio of 10:1. The majority of
patients with SSc-aPAH in the REVEAL cohort were white
(84%), compared with only 37% of SLE-aPAH patients.
Approximately one-third of patients with SSc-aPAH and
MCTD-aPAH were reported to suﬀer from Raynaud phe-
nomenon, compared with 14% of patients with SLE-aPAH
(P<0.0001). Although other studies have estimated the
prevalence of Raynaud phenomenon in SSc and SLE to be
as high as 90% and 45%, respectively, the registry revealed
low numbers for both SLE and SSc due to underreporting of
this data in the REVEAL registry [6, 11, 15–18].
Two large cohort studies have examined the diﬀerences
in treatment of SLE-aPAH versus SSc-aPAH. SLE-aPAH pa-
tients were more likely to receive immunosuppressive ther-
apies in both US and UK cohorts. In the REVEAL cohort
(US), 22% of SLE-aPAH patients received immunosuppres-
sive therapy versus 6.8% of SSc-aPAH patients. Due to
the diﬀerent therapeutic approaches, nearly four times as
many UK based cohort patients with SLE-aPAH received
immunosuppressive therapy [5, 6].
3. Pathobiology of SystemicLupus
Erythematosus-Associated
Pulmonary Hypertension
Although a causal relationship between SLE and PH has not
beenestablished,thevariouselementsofSLE,fromvasculitisClinical and Developmental Immunology 3
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Figure 1: Pathophysiology of pulmonary hypertension in systemic lupus erythematosus. Pulmonary venoocclusive disease (PVOD);
pulmonary capillary hemangiomatosus (PCH); left ventricle (LV).
and in-situ thrombosis to interstitial pulmonary ﬁbrosis, can
lead to endothelial and smooth muscle proliferation and
damage of the pulmonary vasculature resulting in PH [16–
18, 28]. Increased pulmonary vascular resistance may result
from multiple mechanisms in patients with SLE-aPAH, in-
cluding hypoxia due to lung disease (hypoxic vasoconstric-
tion), pulmonary venous hypertension due to left heart
disease, antiphospholipid antibody predisposing to in-situ
thrombosis or acute/chronic thromboemboli, high output
statefromnoncirrhoticportalhypertension,andpulmonary
venoocclusive disease (PVOD)/pulmonary capillary heman-
giomatosis (PCH) [29–35] (refer to Figure 1).
Autopsy ﬁndings in multiple reports suggest multifac-
torial mechanisms for SLE-aPAH. Vascular pathologic ﬁnd-
ings in patients with SLE-aPAH are similar to those in
patients with IPAH, including the plexiform lesions, muscu-
lar hypertrophy, and intimal proliferation [36]. In addition,
studies have shown an imbalance between vasoconstric-
tors and vasodilators in SLE-aPAH, with higher levels of
endothelin-1 [37] and thromboxane A2 and an inhibition
of prostacyclin production by endothelial cells. It should be
noted that these imbalances (elevation of thromboxane A2
and inhibition of prostacyclin) have not been shown speciﬁ-
callyinSLEpatientsandareextrapolatedfromIPAHandSSc
Table 2: Pathology of systemic lupus erythematosus associated
pulmonary hypertension.
Pathological changes in arteries, arterioles and veins
(i) Medial hypertrophy
(ii) Chronic intimal ﬁbrosis
(iii) Periadventitial ﬁbrosis
(iv) Alteration of elastic laminae
(v) Necrotizing ﬁbrinoid arteriopathy
(vi) Aneurysmal dilatation and plexiform lesions
Pathological changes in Thrombotic Arteriopathy
(i) Intimal eccentric ﬁbrous thickening
(ii) Luminal occlusion with recanalization
(iii) Plexiform lesions coexistent with intimal thrombotic lesions
in some arteries
(iv) Concentric laminar intimal ﬁbrosis not present
data. Another key mechanism involves immunoglobulin and
complement deposition in the arterial walls[38, 39]. Tables2
and 3 summarize the pathology and the key causative mech-
anisms in pulmonary arterial hypertension due to systemic
lupus erythematosus [40–64].4 Clinical and Developmental Immunology
Table 3: Key causative mechanisms of PAH in systemic lupus erythematosus.
Mechanisms similar to IPAH patients
(i) Overactivation of transcription factors (hypoxia inducible factor-1 alpha and Nuclear Factor of activated T lymphocytes)
(ii) Decreased expression of certain voltage gated potassium channels
(iii) De novo expression of the antiapoptotic proteins
Mechanisms involving inﬂammation and autoimmunity
(i) Chronic inﬂammation caused by viral infections and autoimmune diseases, leading to the migration of monocytes, neutrophils, mast
cells, and dendritic cells to the structurally damaged pulmonary artery
(ii) Invasion of the elastic lamina, stimulating the release of chemokines, cytokines and growth factors
(iii) Resultant vascular remodeling, collagen deposition, and uninhibited proliferation of endothelial cell
Immune dysregulation mechanism
(i) Decreased percentage of CD4+/CD25+ T cells, diminished regulation by regulatory T cells and B cells, and stimulated signals to B cells
Pathology involving autoantibodies
Antiendothelial cell antibodies (AECA)
(i) AECA prevalence ranges from 15% to 80%
(ii) AECA levels are increased in active SLE, in particular in patients with nephritis, PH and vascular injuries.
(iii) AECA enhances release of endothelin-1
(iv) Binding of AECA or immune complexes may augment release of interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α)
Antiphospholipid antibodies (aPL)
(i) Present in 40% of patients with SLE
(ii) aPLs activate the endothelial cells, monocytes, and platelets leading to a prothrombotic state
Other autoantibodies in SLE-associated PAH
(i) Antinuclear antibody (ANA) invariably present
(ii) >25% prevalence of ribonuclear protein (RNP)
(iii) 50% to 80% prevalence of rheumatoid factor (RF)
Immune and inﬂammatory mechanisms may play a sig-
nificant role in the pathogenesis or progression of PAH,
especially in patients with connective tissue diseases, es-
tablishing a role for anti-inﬂammatory/immunosuppressive
therapy. The inﬂammatory hypothesis in PAH has been val-
idated in multiple studies, due to the ﬁnding of inﬁltration
of macrophages and lymphocytes in the plexiform lesions.
Similarly, the ﬁnding of IgG and complement in the pul-
monary artery walls lends support to the immune hypoth-
esis. Furthermore, in support of the immune mechanism,
researchers have found elevated serum levels of proinﬂam-
matory cytokines and overexpression of growth factors in
diseased pulmonary arteries of severe PAH patients [4, 40,
49, 52].
Figure 2 is a diagrammatic representation of the role of
inﬂammation and dysregulated immune response in the de-
velopment of PAH in SLE [52].
4.ClinicalFeatures
The most common presenting symptoms of SLE-aPAH are
dyspnea, chest pain, dry cough, and fatigue. The onset of
PH in patients with SLE does not correlate with disease
duration or the degree of extrapulmonary manifestations of
the illness, and patients may present with PH in advance of
their diagnosis of SLE. Physical ﬁndings of elevated jugular
venous pressure, ﬁxed S2, murmurs of tricuspid or pulmonic
insuﬃciency, liver enlargement ascites, and lower extremity
edema occur as a consequence of right ventricular strain,
enlargement, or failure.
The study by Lian et al. [65] examines the predictors
contributing to SLE-aPAH as shown in Table 4. By using
univariate and multivariate regression models, the authors
identiﬁed the leading predictors of PAH in SLE to be Ray-
naud phenomenon, anti-U1 RNP antibody, anticardiolipin
antibody positivity, and serositis (statistically signiﬁcant in
theunivariateregressionmodelonly),notedas §inthetable.
Echocardiography to evaluate pulmonary artery pressure
and right heart function is recommended in SLE patients
with these leading independent predictors. Additionally, pa-
tientswithSLE-aPAHtendtohaveahighSLEdiseaseactivity
index score.
The extrapulmonary symptom of Raynaud phenome-
non, one of the major predictors of PAH in SLE, is present
in 75% of patients with SLE-aPAH and in 10%–45% of all
patients with SLE [11, 17, 18].
Pleural eﬀusions are uncommon in pulmonary arterial
hypertension. In a study of 89 patients with PAH associated
with CTD, Luo et al. [66], demonstrated that 39.3% of the
patients had trace to small and bilateral pleural eﬀusions
including37.5%ofthepatients(6outof16)withSLE-aPAH.
When compared with the patients without pleural eﬀusions,
the patients with pleural eﬀusions had signiﬁcantly higher
mean right atrial pressures and lower cardiac indices.
Exercise intolerance is common in patients with SLE.
However, the assessment of these patients can be con-
fusing and diﬃcult because the intolerance could also beClinical and Developmental Immunology 5
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Figure 2:RoleofinﬂammationandDysregulatedimmuneresponseinthedevelopmentofPAHinSLE.(A)Viralinfection,AECA,andother
agents damage the normal pulmonary endothelium. (B) Increase in chemokine/cytokine concentrations as a result of endothelial injury,
leading to recruitment of dendritic cells, mast cells, B cells, and T cells. (C) Inﬁltration of the small, and medium-sized pulmonary arteries
by the dendritic cells, mast cells, B cells and T cells, resulting in dysregulated angiogenesis. AECA: antiendothelial cell antibodies; RANTES:
regulated upon activation, normal T cell expressed and secreted; CCL5: chemokine Ligand 5; CX3CLI: chemokine Ligand 1 [Fractalkine];
IL-1: interleukin-1; IL-6: interleukin-6; PDGF: platelet derived growth factor.
attributed to other concomitant conditions such as physical
deconditioning, arthritis/arthralgias, obesity, myopathy or
neuropathy [39].
5. Antiphospholipid Syndrome
Antiphospholipid syndrome (APS), deﬁned as the contin-
uous presence of antiphospholipid antibody (aPL) with
arterial, venous, or small vessel thrombosis, with or without
recurrent pregnancy losses, can occur in association with
SLE. The high prevalence of antiphospholipid antibodies
in SLE-aPAH patients is well known, occurring in 83% of
patients with SLE-aPAH and in 30% to 50% of patients with
SLE without PAH, compared to 7% in patients with systemic
sclerosis. These antibodies have been reported in 10% to
15% of IPAH patients who may be at risk for developing an
underlying CTD, such as SLE, later on in the disease course.
Pathogenic aPLs activate the endothelial cells, mono-
cytes, and platelets leading to a prothrombotic state. Patients
with these antibodies are more susceptible to developing
thrombotic arteriopathy and therefore require a careful as-
sessment for chronic thromboembolic pulmonary hyperten-
sion (CTEPH). Increased levels of circulating endothelin-
1 have been reported in patients with aPL, possibly con-
tributingtovasoconstrictionandPAH[47–51].Patientswith6 Clinical and Developmental Immunology
Table 4: Possible risk factors for the development of PH in systemic
lupus erythematosus.
(i) Female gender
(ii) Isolated reduction in diﬀusion
(iii) Raynaud phenomenon §
(iv) Serositis §
(v) Renal disease
(vi) Digital gangrene
(vii) Cutaneous vasculitis/livedo reticularis
(viii) Rheumatoid factor
(ix) Anti-U1 RNP §
(x) Anticardiolipin antibodies §
(xi) Antiendothelial cell antibodies
APS and SLE with high levels of aPL also have increased
prevalence of valvular disease (Libman-Sacks endocarditis)
which can contribute to pulmonary venous hypertension.
6.Diagnosis
PAH may be suspected due to ﬁndings on routine chest
radiography and/or 12-lead electrocardiogram, obtained in
the evaluation of dyspnea. Computerized tomography of the
lung to rule out pulmonary parenchymal abnormalities is
not recommended in the absence of abnormalities on phys-
ical exam, routine chest radiograph, or pulmonary function
testing. The ﬁrst-line of diagnostic testing for patients with
suspected SLE-aPAH involves obtaining a Doppler echocar-
diogram to look for elevations in estimated pulmonary
artery pressure and/or tricuspid valve insuﬃciency. The
estimation of pulmonary artery pressure (PAP) by Doppler
echocardiography (DE) does not necessarily correlate with
the measurement of PAP obtained directly by RHC [67–69].
During the RHC, vasodilator agents such as nitric oxide,
epoprostenol or adenosine may be used to identify vasore-
activity. DE may, in some instances, be used in lieu of the
RHC to follow patients while on therapy; right ventricular
parameterssuchastricuspidannularplanesystolicexcursion
(TAPSE) and right ventricular fractional area change could
be useful indices for evaluating right ventricular function.
RHC is required to conﬁrm the diagnosis and assess the
severityofPHandalsotoprovidedeﬁnitiveassessmentwhile
on therapy. Most patients in this SLE-aPAH population are
not vasoreactive and calcium channel blocker therapy has
not proven to be beneﬁcial. The mPAP of >30mmHg during
exercise is no longer considered to be part of the deﬁnition of
PAH as the normal baseline mPAP for exercise had not been
established.
Other studies to consider as part of the evaluation for
secondary causes of PH, even in a patient with known SLE,
include polysomnography to evaluate for sleep disordered
breathing, testing for human immunodeﬁciency virus, hep-
atitis serology, pulmonary function tests (the ﬁnding of an
isolated defect in diﬀusing capacity for carbon monoxide on
lung function testing may be an early predictor of SLE-aPAH
[70]), and ventilation perfusion scan to evaluate for acute or
chronic thromboemboli.
7. Treatment
SLE-aPAH patients are generally treated with therapies such
as oxygen, anticoagulants, calcium channel blockers, and
vasodilators, similar to the therapeutic interventions for
patients in WHO Group I. However, no single therapeutic
regimen has been shown to be fully eﬀective in treating
SLE-aPAH.Thevasodilatorsemployedareselectiveandnon-
selective endothelin receptor antagonists (ETRAs), phos-
phodiesterase-5-inhibitors (PDE-5-I), and oral, inhaled,
subcutaneous, or intravenous prostanoids [1].
The key ﬁndings in the vasodilator trials (summarized in
Table 5) show improvement in exercise capacity, hemody-
namic parameters, New York Heart Association Functional
Class, increase in time to clinical worsening, and a trend
towards improved quality of life in CTD-aPAH patients. The
number of patients with SLE-aPAH in these trials was small,
and most studies did not perform subgroup analysis for SLE-
aPAH patients. As a result, no deﬁnitive conclusion can be
drawn for this subgroup of patients. However, one study by
Badesch et al., on behalf of the SUPER study group (SUPER
1), performed a posthoc analysis to study the eﬃcacy of
sildenaﬁl on CTD-aPAH patients (n = 278) of which 23%
had SLE-aPAH. This double-blinded study showed signif-
icant improvement in pulmonary hemodynamics, exercise
capacity, and WHO functional class with 20 mgs of Sildenaﬁl
over a 12-week period [22].
As discussed earlier, patients with aPLs are more suscep-
tible to in-situ thrombosis and thrombotic arteriopathy and
should be screened for chronic thromboembolic pulmonary
hypertension (CTEPH). Once diagnosed, the CTEPH pa-
tients require diﬀerent modalities of treatment [71–75].
Another important condition seen in patients with PH
associated with SLE is mitral and aortic valvular pathology
(referred to as Libman-Sacks endocarditis) causing regurgi-
tation and leading to pulmonary venous hypertension. The
precise incidence has not been determined and eﬀective
treatment is unavailable [76–81].
As discussed in the pathology section, SLE-aPAH results
from sustained pulmonary vasoconstriction leading to lumi-
nal obliteration of small and medium-sized pulmonary
arteries, due to the formation of plexiform lesions and in-
situ thrombosis. In addition, inﬂammatory and dysregulated
immune components play a major role in the pathogenesis
of PAH in SLE leading to therapy with anti-inﬂammatory
glucocorticoids and immunosuppressive therapies, a subject
of on-going investigation [19–21, 23–27, 82–84].
Table 5 delineates the various treatment modalities and
their respective outcomes in patients with SLE-aPAH. In the
studies summarized in the table, all patients had RHC for
diagnosis of PAH. It should be noted that the immunosup-
pressive therapy trials to date have been small nonrandom-
ized, observational, retrospective, uncontrolled studies (with
historical controls) and case reports, whereas the vasodilator
treatment studies are mostly randomized controlled studies
with a small number of SLE-aPAH patients. Additional com-
prehensive and controlled trials are needed to test the
eﬀectiveness of immunosuppressive therapies in the SLE-
aPAH patients.Clinical and Developmental Immunology 7
Table 5: Treatment modalities and respective outcomes for SLE-aPAH patients. Mean pulmonary artery pressure (MPAP) in mmHg;
pulmonary vascular resistance (PVR) in Woods units; 6 minute walk distance (6MWD) in meters; age in years; New York Heart Association
Functional class (NYHA FC); Average (avg.).
Studies Drug/design Patients and baseline characteristics Outcome
Intensive Immunosuppressive therapy (IIT) trials
IIT: IV cyclophosphamide +
oral glucocorticoids +
vasodilator therapy (VT)
(i) 8 patients with SLE-aPAH IIT:
(ii) MPAP = 39.5 ± 9.2 (i) Signiﬁcantly decreased MPAP
(iii) PVR = 8.75 ± 5.43 (ii) Tended to decrease PVR Miyamichi-Yamamoto
et al. [19] (iv) NYHA FC = I, II, III (iii) Normalized hemodynamics
in a few patients.
(v) 6MWD = 442 ± 54 IIT + VT improved the
Observational cohort study
from a single center with
historical control
(vi) Age = 42 ± 8
pulmonary hemodynamics and
long-term prognosis of patients
with CTD-aPAH.
IIT: IV cyclophosphamide +
glucocorticoids + VT
Rx with
IIT
Rx with
IIT + VT
(i) SLE-aPAH patients with less
severe disease may respond to
treatment with IIT.
N = 13 9 4 (ii) For patients with more severe
disease, VT should be started,
MPAP 48 ± 12 58 ± 10 possibly in combination with IIT. Jais et al. [20]
PVR 8.6 ± 3.5 14.3 ± 1.3 (iii) These retrospective and
uncontrolled data need to be
conﬁrmed by randomized
controlled trials.
Retrospective, uncontrolled
study NYHA II, III III, IV
FC
6MWD 347 ± 80 381 ± 71
Age 31 ± 10 38 ± 9
IV cyclophosphamide ±
glucocorticoids
(i) 13 patients with SLE-aPAH (i) Of the responders [R] 62% had
SLE.
(ii) MPAP (avg.) = 54 (ii) R’s had a signiﬁcantly improved
6MWD and hemodynamic
parameters.
Sanchez et al. [21]
Retrospective study
(iii) PVR (avg.) = 19
(iv) NYHA FC = II, III (iii) R’s had a better survival than
non responders [NR].
(v) 6MWD (avg.) = 370
(vi) Age (avg.) = 29
Oral agents: endothelin receptor antagonists (ETRAs) and phosphodiesterase-5-inhibitors (PDE-5-I)
Sildenaﬁl20mg,40mg,80mg (i) 19 patients with SLE-aPAH In patients with PAH-aCTD,
sildenaﬁl improves exercise
capacity, hemodynamic parameters
(at the 20mg dose), and NYHA FC
after 12 weeks of treatment.
(ii) MPAP = 47 ± 11
Badesch et al. [22] 12 week, double-blind study
(SUPER-1)
(iii) PVR = 10.13 ± 5.45
(iv) NYHA FC = II, III, IV
(v) 6MWD = 342 ± 76
(vi) Age = 53 ± 15
Sildenaﬁl20mg,40mg,80mg (i) 19 patients with SLE Sildenaﬁl improves exercise capacity
and hemodynamics in patients with
symptomatic PAH. SLE-aPAH
subgroup analysis was not done.
(ii) MPAP = 52.75 ± 14
Gali` ee ta l .[ 23] Double-blind
placebo-controlled trial
(iii) PVR = 11.95 ± 6.29
(iv) NYHA FC = II, III, IV
(v) 6MWD = 344 ± 82
(vi) Age = 49 ± 158 Clinical and Developmental Immunology
Table 5: Continued.
Studies Drug/design Patients and baseline characteristics Outcome
Bosentan (i) 16 patients with SLE
(ii) MPAP = 55 ± 16 Statistically signiﬁcant
improvement in exercise capacity,
NYHA FC and increase in time to
clinical worsening.
Rubin et al. [24] Double-blind
placebo-controlled
(iii) PVR = 12.68 ± 8.48
trial (iv) NYHA FC = III, IV
(v) 6MWD = 330 ± 74
(vi) Age = 49 ± 16
Subcutaneous, inhaled, and intravenous prostanoids
Subcutaneous treprostinil (i) 25 patients with SLE
(ii) MPAP = 52 ± 2 Improved exercise capacity, dyspnea
fatigue symptoms, hemodynamics
and trend toward improved quality
of life.
Oudiz et al. [25] (iii) NYHA FC = II, III, IV
Double-blind
placebo-controlled trial
(iv) 6MWD = 280 ± 13
(v) Age = 54 ± 2
Inhaled Iloprost (i) 35 patients with CTD (i) Statistically signiﬁcant beneﬁt in
combined endpoint of 10%
improvement in 6MWD and FC
improvement and absence of
clinical deterioration.
Olschewski et al. [26] (ii) MPAP = 52.8 ± 11.5
Randomized
placebo-controlled trial
(iii) PVR = 12.86 ± 4.88
(iv) NYHA FC = III, IV
(v) 6MWD = 332 ± 93
(vi) Age = 51 ± 13 (ii) No subgroup analysis done for
SLE.
Intravenous epoprostenol (i) 6 patients with SLE
Dramatic improvement in FC and
marked improvement in
hemodynamics.
(ii) MPAP = 57 ± 9
Robbins et al. [27] Case series (iii) PVR = 14 ± 7
(iv) NYHA FC = III, IV
(v) Age = 26–35
Intensive immunosuppressive therapy (IIT) is deﬁned
as an intravenous (IV) bolus of cyclophosphamide 500–
600mg/m2 monthly for 3–6 months in addition to oral
glucocorticoids 0.5–1mg/kg/day for 4 weeks followed by a
slow taper. In the three studies [19–21] highlighted in the
table, variations of above mentioned doses and time periods
of administration of cyclophosphamide and oral or intra-
venous glucocorticoids were used.
8. Other Therapies
Atrial septostomy and lung or heart-lung transplantation
maybeanoptionforsomepatientswithSLE-aPAHwhohave
failed maximized medical therapy and continue to have dis-
ease progression (acceptance for transplant maybe predi-
cated upon quiescence of other systemic manifestations of
SLE) [85]. IPAH patients have a better prognosis than SLE-
aPAH patients. Most patients with SLE-aPAH are women of
a child bearing age, and due to the high maternal mortality
in this group, screening for PH in pregnant mothers is
recommended [86–90].
9.Survival
Theone-andthree-yearsurvivalratesforSLE-aPAHare78%
and 74% respectively [2, 5]. While the one-year survival rate
of SSc-aPAH patients is similar to that of SLE-aPAH patients,
the three-year survival rate is much lower at 47%. The
REVEAL cohort of patients with SLE-aPAH had a one-year
survival rate of 94% [6]. The advanced therapy including
immunosuppression given to SLE-aPAH patients early in the
course of disease may account for the improved survival
rates, despite similar abnormalities in baseline pulmonary
hemodynamics in both patient groups. However, if other
respiratory disorders coexist with PH, the prognosis is
similar to that of patients with SSc-aPAH.
Quadrelli et al. [91] examined 90 SLE necropsies and
found 97.8% to have some pleuropulmonary involvement
but not necessarily related to SLE. The most frequent lung
ﬁnding was bacterial bronchopneumonia (a contributing
cause of death) in 90% followed by pleuritis in 88%. Four
out of 90 patients had ﬁndings of pulmonary hypertension
(4.4%). In another study [92], pulmonary arterial hyper-
tension was the third most common cause of death, after
infection and lupus manifestations other than renal involve-
ment. The patients in the latter study were on higher doses of
corticosteroids preceding their death.
10. Conclusions
Connective tissue disease-associated PAH has historically
had a poor prognosis with a one-year survival rate ofClinical and Developmental Immunology 9
45% in patients with SSc-aPAH. Recent survival rates of all
CTD-aPAH have improved, in part due to the advances in
therapies,althoughthesemodalitiesrequirefurtherstudy.To
date, most of the research has focused on SSc-aPAH, leaving
insuﬃcient data on the other CTD-aPAH. Jais, Sanchez, and
colleagues [19–21, 82] have studied SLE-aPAH and the eﬀect
of intensive immunosuppressive therapy on the survival
rates. The linkage between intensive immunosuppressive
therapy and improved survival rates is not yet conclusive due
to the paucity of randomized placebo-controlled studies.
These studies are diﬃcult to conduct because there are few
patients with this disease who are not already on therapy.
However, patients should be treated aggressively with im-
munosuppressive and anti-inﬂammatory therapies, coupled
with vasodilator therapy due to progression of disease. In
certain cases, an initial combination of intensive immuno-
suppressive and vasodilator therapies may be used [93, 94].
Todate,therehavenotbeenconsensusrecommendations
for screening for PH in patients with SLE. However, young
women of child bearing age are most at risk of dying due to
undiagnosedSLE-aPAHduringpregnancy,delivery,andpost
partum. Therefore, screening should be considered essential
in this population. Patients with anti-U1 RNP antibody, an-
ticardiolipin antibody, and Raynaud phenomenon should
also be seriously considered for screening, given the high
correlation between these predictors and PH.
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